

Kathryn S Torok

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3191080/publications.pdf>

Version: 2024-02-01

68
papers

1,665
citations

361413

20
h-index

315739

38
g-index

69
all docs

69
docs citations

69
times ranked

1126
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and initial validation of the Localized Scleroderma Skin Damage Index and Physician Global Assessment of disease Damage: a proof-of-concept study. <i>Rheumatology</i> , 2010, 49, 373-381.	1.9	171
2	The Localized Scleroderma Skin Severity Index and Physician Global Assessment of Disease Activity: A Work in Progress Toward Development of Localized Scleroderma Outcome Measures. <i>Journal of Rheumatology</i> , 2009, 36, 2819-2829.	2.0	147
3	Development of consensus treatment plans for juvenile localized scleroderma: A roadmap toward comparative effectiveness studies in juvenile localized scleroderma. <i>Arthritis Care and Research</i> , 2012, 64, 1175-1185.	3.4	137
4	Cytokine profiles in localized scleroderma and relationship to clinical features. <i>Cytokine</i> , 2011, 55, 157-164.	3.2	98
5	Methotrexate and Corticosteroids in the Treatment of Localized Scleroderma: A Standardized Prospective Longitudinal Single-center Study. <i>Journal of Rheumatology</i> , 2012, 39, 286-294.	2.0	91
6	The Localized Scleroderma Cutaneous Assessment Tool: Responsiveness to change in a pediatric clinical population. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 214-220.	1.2	91
7	Pediatric Scleroderma: Systemic or Localized Forms. <i>Pediatric Clinics of North America</i> , 2012, 59, 381-405.	1.8	77
8	Immunopathogenesis of Pediatric Localized Scleroderma. <i>Frontiers in Immunology</i> , 2019, 10, 908.	4.8	62
9	Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 284-293.	3.4	59
10	Development of minimum standards of care for juvenile localized scleroderma. <i>European Journal of Pediatrics</i> , 2018, 177, 961-977.	2.7	45
11	Interferon-gamma inducible protein-10 as a potential biomarker in localized scleroderma. <i>Arthritis Research and Therapy</i> , 2013, 15, R188.	3.5	40
12	Predictors of Longitudinal Quality of Life in Juvenile Localized Scleroderma. <i>Arthritis Care and Research</i> , 2017, 69, 1082-1087.	3.4	37
13	Baseline Description of the Juvenile Localized Scleroderma Subgroup From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry. <i>ACR Open Rheumatology</i> , 2019, 1, 119-124.	2.1	36
14	Prediction of disease relapse in a cohort of paediatric patients with localized scleroderma. <i>British Journal of Dermatology</i> , 2019, 180, 1183-1189.	1.5	35
15	Autoantibodies in Morphea: An Update. <i>Frontiers in Immunology</i> , 2019, 10, 1487.	4.8	29
16	A Case Report of Successful Treatment of Recalcitrant Childhood Localized Scleroderma with Infliximab and Leflunomide. <i>Open Rheumatology Journal</i> , 2015, 9, 30-35.	0.2	27
17	Clinical Characteristics and Factors Associated With Disability and Impaired Quality of Life in Children With Juvenile Systemic Sclerosis: Results From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry. <i>Arthritis Care and Research</i> , 2018, 70, 1806-1813.	3.4	26
18	Identifying the Signature Immune Phenotypes Present in Pediatric Localized Scleroderma. <i>Journal of Investigative Dermatology</i> , 2019, 139, 715-718.	0.7	25

#	ARTICLE	IF	CITATIONS
19	New Features for Measuring Disease Activity in Pediatric Localized Scleroderma. <i>Journal of Rheumatology</i> , 2018, 45, 1680-1688.	2.0	24
20	Immunopathogenesis of Juvenile Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2019, 10, 1352.	4.8	23
21	Initial Results from a Pilot Comparative Effectiveness Study of 3 Methotrexate-based Consensus Treatment Plans for Juvenile Localized Scleroderma. <i>Journal of Rheumatology</i> , 2020, 47, 1242-1252.	2.0	21
22	Single-cell transcriptome conservation in a comparative analysis of fresh and cryopreserved human skin tissue: pilot in localized scleroderma. <i>Arthritis Research and Therapy</i> , 2020, 22, 263.	3.5	21
23	Are diffuse and limited juvenile systemic sclerosis different in clinical presentation? Clinical characteristics of a juvenile systemic sclerosis cohort. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 49-61.	1.7	20
24	A28: Description of the Juvenile Localized Scleroderma Subgroup of the CARRA Registry. <i>Arthritis and Rheumatology</i> , 2014, 66, S43-S44.	5.6	18
25	Hypocomplementemia Associated with Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still's Disease: 3 Cases: Table 1.. <i>Journal of Rheumatology</i> , 2011, 38, 396-397.	2.0	16
26	Extracutaneous involvement is common and associated with prolonged disease activity and greater impact in juvenile localized scleroderma. <i>Rheumatology</i> , 2021, 60, 5724-5733.	1.9	16
27	Preliminary evidence on abatacept safety and efficacy in refractory juvenile localized scleroderma. <i>Rheumatology</i> , 2021, 60, 3817-3825.	1.9	16
28	Coronary artery involvement in pediatric Takayasu's arteritis: Case report and literature review. <i>Pediatric Rheumatology</i> , 2013, 11, 4.	2.1	15
29	Brief Report: HLA-DRB1, DQA1, and DQB1 in Juvenile-Onset Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2016, 68, 2772-2777.	5.6	15
30	Exploring the impact of paediatric localized scleroderma on health-related quality of life: focus groups with youth and caregivers. <i>British Journal of Dermatology</i> , 2020, 183, 692-701.	1.5	15
31	An Evaluation of the Performance of Current Morphea Subtype Classifications. <i>JAMA Dermatology</i> , 2021, 157, 399.	4.1	15
32	Genetic Signatures From RNA Sequencing of Pediatric Localized Scleroderma Skin. <i>Frontiers in Pediatrics</i> , 2021, 9, 669116.	1.9	15
33	Reliability and validity of the delta finger-to-palm (FTP), a new measure of finger range of motion in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, S28-36.	0.8	14
34	Autoimmune thyroiditis in antinuclear antibody positive children without rheumatologic disease. <i>Pediatric Rheumatology</i> , 2010, 8, 15.	2.1	13
35	Underdetection of Interstitial Lung Disease in Juvenile Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2022, 74, 364-370.	3.4	13
36	Differences Sustained Between Diffuse and Limited Forms of Juvenile Systemic Sclerosis in an Expanded International Cohort. <i>Arthritis Care and Research</i> , 2022, 74, 1575-1584.	3.4	13

#	ARTICLE	IF	CITATIONS
37	Detection of autoimmune antibodies in localized scleroderma by synthetic oligonucleotide antigens. PLoS ONE, 2018, 13, e0195381.	2.5	12
38	Linear Scleroderma of the Head - Updates in management of Parry Romberg Syndrome and En coup de sabre: A rapid scoping review across subspecialties. European Journal of Rheumatology, 2020, 7, S48-S57.	0.6	12
39	A novel patient-reported outcome for paediatric localized scleroderma: a qualitative assessment of content validity. British Journal of Dermatology, 2020, 182, 625-635.	1.5	11
40	Durometry as an outcome measure in juvenile localized scleroderma. British Journal of Dermatology, 2016, 174, 228-230.	1.5	10
41	Developing comparative effectiveness studies for a rare, understudied pediatric disease: lessons learned from the CARRA juvenile localized scleroderma consensus treatment plan pilot study. Pediatric Rheumatology, 2019, 17, 43.	2.1	10
42	Unilateral Neuroimaging Findings in Pediatric Craniofacial Scleroderma: Parry-Romberg Syndrome and En Coup de Sabre. Journal of Child Neurology, 2020, 35, 753-762.	1.4	9
43	Transcriptomic Evaluation of Juvenile Localized Scleroderma Skin With Histologic and Clinical Correlation. Arthritis and Rheumatology, 2021, 73, 1921-1930.	5.6	9
44	Chronic Recurrent Multifocal Osteomyelitis of the Mandible: A Diagnostic Challenge. Plastic and Reconstructive Surgery, 2018, 142, 186-192.	1.4	8
45	A48: Durometer Measures Discriminate Affected versus Normal Skin in Pediatric Localized Scleroderma. Arthritis and Rheumatology, 2014, 66, S72-S73.	5.6	6
46	Psychometric properties of the Children's Dermatology Life Quality Index in pediatric localized scleroderma. Journal of Scleroderma and Related Disorders, 2018, 3, 175-181.	1.7	6
47	Review for best practice in clinical rheumatology juvenile systemic sclerosis – Updates and practice points. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101688.	3.3	6
48	The importance of development standards for anchoring vignettes: an illustrative example from pediatric localized scleroderma quality of life. Quality of Life Research, 2020, 29, 3263-3272.	3.1	5
49	Updates in Systemic Sclerosis Treatment and Applicability to Pediatric Scleroderma. Rheumatic Disease Clinics of North America, 2021, 47, 757-780.	1.9	5
50	DNA methylation patterns in juvenile systemic sclerosis and localized scleroderma. Clinical Immunology, 2021, 228, 108756.	3.2	4
51	Efficacy and cost savings with the use of a minimal sedation / anxiolysis protocol for intra-articular corticosteroid injections in children with juvenile idiopathic arthritis: a retrospective review of prospectively collected data. Pediatric Rheumatology, 2019, 17, 11.	2.1	3
52	Assigning values to the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) score indicating degree of severity and responsiveness: fostering practical use in clinic and therapeutic studies for morphea/localized scleroderma. British Journal of Dermatology, 2020, 182, 272-273.	1.5	3
53	Combined Assay for Detecting Autoantibodies to Nucleic Acids and Apolipoprotein H in Patients with Systemic Lupus Erythematosus. Methods in Molecular Biology, 2020, 2063, 57-71.	0.9	3
54	Prior elicitation of the efficacy and tolerability of Methotrexate and Mycophenolate Mofetil in Juvenile Localised Scleroderma. AMRC Open Research, 0, 3, 20.	1.7	2

#	ARTICLE	IF	CITATIONS
55	Revealing novel, latent subsets of patients with morphea through principal component analysis. <i>British Journal of Dermatology</i> , 2022, 186, 193-195.	1.5	2
56	Improvement in medication education in a pediatric subspecialty practice. <i>Pediatric Rheumatology</i> , 2010, 8, 25.	2.1	1
57	SAT0256â€¦Juvenile Systemic Sclerosis Cohort within The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry: Baseline and Follow Up Characteristics. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 761.2-761.	0.9	1
58	Evaluation and Treatment of Pediatric Localized Scleroderma: Pearls and Updates. <i>Current Treatment Options in Rheumatology</i> , 2021, 7, 1-20.	1.4	1
59	Canakinumab for the treatment of adult and pediatric cryopyrinâ€associated periodic syndromes (CAPS). <i>Drug Development Research</i> , 2011, 72, 553-560.	2.9	0
60	Emotional and mental health impact of morphea demonstrated in adults. <i>British Journal of Dermatology</i> , 2015, 172, 1188-1190.	1.5	0
61	SAT0257â€¦Update on The Juvenile Systemic Sclerosis Inception Cohort Project. Characteristics of The First 74 Patients at First Assessment. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 761.3-762.	0.9	0
62	THU0229â€¦Is There A Difference in The Presentation of Diffuse and Limited Subtype in Childhood? Results from The Juvenile Scleroderma Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 271.1-271.	0.9	0
63	THU0230â€¦Is There A Difference in The Presentation of Male and Female Patients with Juvenile Systemic Sclerosis? Results from The Juvenile Scleroderma Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 271.2-271.	0.9	0
64	AB0967â€¦IS THERE A DIFFERENCE IN PRESENTATION OF FEMALE AND MALE PATIENTS WITH JUVENILE SYSTEMIC SCLERODERMA. AN UPDATE FROM THE JUVENILE SYSTEMIC SCLERODERMA INCEPTION COHORT. <i>WWW.JUVENILE-SCLERODERMA.COM.</i> , 2019, , .		0
65	SAT0479â€¦UPDATE FROM THE JUVENILE SCLERODERMA INCEPTION COHORT. <i>WWW.JUVENILE-SCLERODERMA.COM.</i> , 2019, , .		0
66	SAT0478â€¦AFTER 24 MONTHS OBSERVATION PERIOD THE PATIENTS RELATED OUTCOMES IMPROVE SIGNIFICANTLY IN THE JUVENILE SCLERODERMA INCEPTIONS COHORT. <i>WWW.JUVENILE-SCLERODERMA.COM.</i> , 2019, , .		0
67	AB0966â€¦PROPOSAL OF OUTCOME MEASURES TO BE USED ON A 12-MONTH OPEN LABEL DRUG TRIAL IN JUVENILE SYSTEMIC SCLEROSIS. RESULTS OF THE 3RD CONSENSUS MEETING IN HAMBURG DECEMBER 2018. , 2019, , .		0
68	An erythematous patch on the ear and face of a young boy. <i>Pediatric Dermatology</i> , 2021, 38, e45-e47.	0.9	0